# A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

> **NCT05599828** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 14 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AMG 510
- **DRUG:** Omeprazole
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT05599828
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2020-09-13
- **Final completion:** 2020-09-13
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599828, "A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05599828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*